[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Larissa University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":196},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,69,96,126,151,171],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100623851","the-correlation-of-lewis-antigens-with-vte-100623851",false,"NCT07402005","The Correlation of Lewis Antigens With VTE","Correlation of Lewis Erythrocyte Antigens With the Risk of Venous Thromboembolic Disease-VTE","Inclusion Criteria:\n\n* Adult patients aged 18-78 years with a personal history of deep venous thrombosis and\u002For Pulmonary Embolism.\n\nExclusion Criteria:1. Current pregnancy or postpartum period 2. Hepatic insufficiency 3. Alcoholic cirrhosis\n\n\\-",true,"ALL","18 Years","78 Years",{"count":21,"type":22},200,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn if certain factors in a person's blood are linked to a history of venous thromboembolic disease (VTED), which includes conditions like deep vein thrombosis.\n\nLewis system antigens are natural markers found on red blood cells. Past research suggests that people without these specific markers might have a higher chance of developing heart disease, but the link to blood clots in veins is not well understood.\n\nThis study aims to answer:\n\n* Are certain Lewis antigen types more common in people with a history of VTE?\n* Do the Lewis antigen results relate to other known blood clot risk factors? Researchers will identify Lewis a and b antigens in 100 participants who attend the Haemostasis Disorders Clinic at the University Hospital of Larissa. All participants are people with a personal history of deep vein thrombosis, with or without an inherited or acquired tendency for blood clots.\n\nResearchers will also record other known risk factors for VTED for each participant. This study is self-funded.",[26],"Thromboembolic Disease",[28],"VTE, LEWIS ANTIGEN","NOT_YET_RECRUITING","2026-02-03",{"date":32,"type":33},"2026-02-11","ACTUAL",{"date":35,"type":22},"2026-01-19",{"date":37,"type":22},"2027-01-18",{"name":39,"class":40},"Larissa University Hospital","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100605423","a-multicenter-prospective-study-for-glioblastoma-patients-100605423","NCT07162324","A Multicenter, Prospective Study for Glioblastoma Patients","Prognostic Factors, Surgical Management and Survival of Glioblastoma Patients: a Multicenter Prospective Study","Inclusion criteria:\n\n* Adult patients (\\>18 years of age) with\n* Glioblastoma based on radiographic features,\n* Patients that consent for study participation.\n\nExclusion criteria:\n\n* Non adult patients,\n* Patients that do not consent for participation in this study,\n* Patients with other CNS tumors",{"count":49,"type":22},100,"Glioblastoma (GBM) is the most common and aggressive primary tumor of the adult central nervous system (CNS), with a poor prognosis and median overall survival ranging between 14 to 20 months despite advancements in diagnostic and therapeutic strategies. This prospective, observational, multicenter study aims to collect and analyze comprehensive data from GBM patients treated across selected centers in Europe and the United States, the investigators' centers included. Information will include demographics, imaging findings, molecular subtypes, clinical status, surgical strategies, postoperative management, complications, and follow-up data. Patients over 18 years old with radiographic evidence of GBM who provide informed consent will be included. Surgical interventions will vary, ranging from biopsy to supramaximal resections, based on individual patient and surgeon decisions. Key outcomes of interest include overall survival (OS) and progression-free survival (PFS). Secondary endpoints include perioperative complications, extent of resection (EoR), pre- and postoperative Karnofsky Performance Scores (KPS), hospital stay duration, and identification of risk factors influencing OS and functional outcomes. Patient monitoring will include standardized follow-up at one, three, and six months postoperatively, and quarterly thereafter or as clinically indicated. Statistical analysis will be conducted using R software, applying descriptive statistics, chi-square tests, logistic and linear regression, and assessing statistical significance at p \\\u003C 0.05. Results will also be expressed in odds ratios with 95% confidence intervals. This study seeks to define optimal surgical strategies based on patient-specific factors and contribute to improved, personalized treatment pathways for GBM management.",[52],"Glioblastoma",[54,55,56,57,58,59],"glioblastoma","lobectomy","complications","outcome","overall survival","progression free survival","2025-09-04",{"date":62,"type":33},"2025-09-09",{"date":64,"type":22},"2025-09-01",{"date":66,"type":22},"2030-12-31",{"name":39,"class":40},3,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100502963","duet-versus-standard-interface-for-hypercapnic-copd-patients-100502963","NCT05829083","DUET Versus Standard Interface for Hypercapnic COPD Patients","Asymmetric (DUET) Versus Conventional Nasal High Flow Interface for Management of Hypercapnic Patients With Mild to Moderate Acute Exacerbation of COPD: A Randomized, Crossover Clinical Trial","Inclusion Criteria:\n\n* acute exacerbation of COPD (defined as any worsening of the patient's respiratory symptoms that is beyond normal day-to-day variations and leads to change in medication)\n* mild-to-moderate acute hypercapnic respiratory failure (defined as 7.35\\>pH\\>7.25 and arterial CO2 tension (PaCO2) \\>45 mmHg)\n\nExclusion Criteria:\n\n* acute on chronic hypercapnic respiratory failure\n* severe facial deformity, facial burns, fixed upper airway obstruction\n* indication for imminent intubation and invasive mechanical ventilation (i.e. respiratory or cardiac arrest, diminished consciousness (Glasgow coma score \\\u003C8)\n* psychomotor agitation inadequately controlled by sedation\n* massive aspiration\n* persistent inability to remove respiratory secretions\n* severe haemodynamic instability unresponsive to fluids and vasoactive drugs\n* severe ventricular or supraventricular arrhythmias\n* life threatening hypoxaemia",{"count":77,"type":22},50,"INTERVENTIONAL",[80],"NA","The goal of this clinical trial is to compare the new asymmetric nasal high flow interface with the conventional high flow nasal cannula in patients with COPD exacerbation.\n\nThe main questions the study aims to answer are:\n\n• Does the use of the asymmetric interface lead to:\n\n1. A greater decrease in the patients' carbon dioxide\n2. A greater decrease in respiratory rate and less dyspnea\n3. Less need for advanced oxygen therapy measures\n4. Same tolerance and comfort\n5. Lower heart rate and blood pressure\n\nParticipants will be asked to:\n\nWear the asymmetric and conventional cannulas for 3 hours each with a 30 minute gap in-between. Arterial blood samples and various clinical parameters will be collected throughout the study period.\n\nResearchers will compare the effect of asymmetric versus conventional cannulas to answer the aforementioned questions.",[83,84,85],"COPD Exacerbation","Hypercapnia","COPD","RECRUITING","2025-09-03",{"date":89,"type":33},"2025-09-10",{"date":91,"type":33},"2023-07-18",{"date":93,"type":22},"2025-12-01",{"name":39,"class":40},2,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":78,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100494109","laparoscopic-versus-open-right-colectomy-for-right-colon-cancer-100494109","NCT05713903","Laparoscopic Versus Open Right Colectomy for Right Colon Cancer","Comparison of Laparoscopic Versus Open Right Colectomy for Right Colon Cancer, According to the Complete Mesocolic Excision (CME) Principles: a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Histologically confirmed right colon cancer (cecum, ascending colon, hepatic flexure)\n* Surgical resection based on the CME principles\n* Patient 18 to 90 years old\n* American Society of Anesthesiologists score ≤III\n* Τ≤3\n* Elective operation\n* Signed informed consent of the patient\n\nExclusion Criteria:\n\n* Non elective operation (hemorrhage, perforation, obstruction)\n* Locally advanced disease (T4)\n* Distant metastases (Stage IV)\n* American Society of Anesthesiologists ≥IV\n* Previous laparotomy\n* BMI \\>35 kg\u002Fm2\n* Active sepsis or systemic infection\n* Untreated physical and mental disability\n* Pregnancy or breast-feeding\n* Lack of compliance with the protocol process\n* Non-granting of signed informed consent","90 Years",{"count":105,"type":22},114,[80],"The purpose of this research protocol is to compare open versus laparoscopic right colectomy (according to the CME technique of complete mesocolic excision) for right colon cancer. This study will be designed as a prospective randomized controlled trial. The comparison of the two techniques will include endpoints regarding the quality characteristics of the specimens and the oncological results. In addition, the effectiveness of the two methods will be evaluated in terms of the early and late postoperative period.",[109],"Colon Cancer",[111,112,113,114,115,116,117,118],"colon","cancer","open","laparoscopic","colectomy","right","mesocolic","excision",{"date":60,"type":33},{"date":121,"type":33},"2023-02-06",{"date":123,"type":22},"2028-01-10",{"name":39,"class":40},1,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":132,"targetDuration":4,"studyType":78,"phases":134,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":125},"100435395","intraoperative-neuromonitoring-of-pelvic-autonomous-nerve-plexus-during-total-mesorectal-excision-100435395","NCT04949646","Intraoperative Neuromonitoring of Pelvic Autonomous Nerve Plexus During Total Mesorectal Excision","Inclusion Criteria:\n\n* Histologically confirmed rectal cancer\n* Surgical resection with TME\n* \\\u003C90 years old\n* Signed informed consent\n\nExclusion Criteria:\n\n* Emergency operation\n* Presence of pacemaker\n* Partial mesorectal excision\n* Sepsis or systematic infection\n* Physical or mental impairment\n* Pregnancy or nursing\n* Insufficient preoperative data for the urogenital\u002F anorectal function\n* Lack of compliance with the research process",{"count":133,"type":22},44,[80],"The purpose of this research protocol is the evaluation of the improvement of the anorectal and urogenital urinary function, alongside the postoperative quality of life after the application of pIONM in patients submitted to TME for rectal cancer.",[137],"Rectal Neoplasms",[139,140,141,142,143,144,118],"intraoperative","neuromonitoring","pelvic","autonomous","total","mesorectal",{"date":60,"type":33},{"date":147,"type":33},"2021-09-19",{"date":149,"type":22},"2028-09-19",{"name":39,"class":40},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":78,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":170,"locationsCount":125},"100598059","the-effect-of-asymmetrical-vs-symmetrical-high-flow-nasal-cannula-on-the-work-of-breathing-100598059","NCT07066566","The Effect of Asymmetrical vs. Symmetrical High Flow Nasal Cannula on the Work of Breathing","The Effect of Asymmetrical vs. Symmetrical High Flow Nasal Cannula on the Work of Breathing: A Randomised Cross-over Study","Inclusion Criteria:\n\n1. age ≥18 years old\n2. absence of symptoms and signs of respiratory failure (SpO2\\>95% at FiΟ2 0.21)\n\nExclusion Criteria:\n\n1. pregnancy\n2. SpO2\\\u003C94% at FiΟ2 0.21\n3. neuromuscular disease\n4. contraindications to esophageal pressure monitoring (e.g., uncontrolled coagulopathy, esophageal disease, nasal trauma, allergy to local lidocaine)",{"count":159,"type":22},30,[80],"The goal of this study randomized single-center crossover study is to evaluate the impact of asymmetrical versus symmetrical nasal high flow (NHF) therapy on work of breathing (WOB). The main question it aims to answer are:\n\n1\\. Does the asymmetrical NHF interface improve the work of breathing compared to the symmetrical NHF interface? Researchers will compare the symmetrical NHF interface to the symmetrical NHF interface to see if the the asymmetrical interface has a greater impact on the work of breathing.\n\nParticipants will :\n\n1. receive NHF via both interfaces (FiO₂ 0.21, 50 L\u002Fmin) for 15 minutes, in random order, with esophageal pressure monitoring and bioelectrical impedance analysis performed.\n2. baseline characteristics will me monitored throughout the interventions\n3. Esophageal pressure and minute ventilation will be monitored.",[163],"Respiratory Disease (Clinically Stable Individuals - Patients Recovered From Respiratory Disease)","2025-07-15",{"date":166,"type":33},"2025-07-18",{"date":168,"type":33},"2024-04-09",{"date":64,"type":22},{"name":39,"class":40},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":78,"phases":180,"briefSummary":181,"conditions":182,"keywords":183,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":125},"100477401","neoadjuvant-chemoradiotherapy-and-consolidation-chemotherapy-for-rectal-cancer-a-randomized-controlled-trial-100477401","NCT05496491","Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Histologically confirmed rectal adenocarcinoma\n* cT3, cT4, threatened CRM \u002F MRF, EMVI (+), ≥N1\n* Multidisciplinary tumor board decision for neoadjuvant treatment\n* Tumor distance from the anal verge \\\u003C15 cm based on endoscopy or magnetic resonance imaging\n* Patient 18 to 80 years old\n* General health condition status WHO 0-1\n* Absence of co-morbidities that may affect treatment\n* Neutrophils \\>1,500 \u002F mm3, platelets \\>100,000 \u002F mm3, hemoglobin\\> 10 g \u002F dL, normal creatinine, and creatinine clearance\\> 50 mL \u002F min\n* Signed informed consent of the patient\n\nExclusion Criteria:\n\n* Distant metastases\n* Non-resectable cancer\n* Contraindications for the administration of chemotherapy\n* Previous pelvic radiotherapy or chemotherapy\n* History of inflammatory bowel disorders\n* History of angina, acute myocardial infarction or heart failure\n* Active sepsis or systemic infection\n* Untreated physical and mental disability\n* Synchronous malignancy\n* Pregnancy or breast-feeding\n* Lack of compliance with the protocol process\n* Non-granting of signed informed consent","80 Years",{"count":179,"type":22},84,[80],"The purpose of this protocol is to compare neoadjuvant chemoradiation plus consolidation chemotherapy before surgical resection with the standard neoadjuvant chemoradiation followed by surgical resection and adjuvant chemotherapy in patients with rectal cancer.",[137],[184,112,185,186,187,144,118],"rectal","neoadjuvant","radiotherapy","chemotherapy","2024-10-07",{"date":190,"type":33},"2024-10-08",{"date":192,"type":33},"2022-08-30",{"date":194,"type":22},"2026-08-30",{"name":39,"class":40},""]